CRF’s Premier Summit Returns to NYC June 24-26

NEW YORK – June 2, 2026 – The Cardiovascular Research Foundation® (CRF®) announced the highly anticipated lineup of late-breaking research to be presented at New York Valves: The Structural Heart Summit^TM. The premier educational meeting for the structural heart community will take place June 24-26, 2026, at the Jacob K. Javits Convention Center, North in New York, NY.

This year’s program will feature 22 late-breaking clinical science and 8 late-breaking innovation presentations that are poised to transform the treatment of structural heart disease. The research will reveal the latest breakthroughs in transcatheter aortic valve replacement (TAVR) and introduce next-generation innovations for mitral and tricuspid valve therapies. These findings are expected to immediately impact clinical practice, helping to refine patient selection, optimize techniques, and define the standard of care for new and emerging treatments.

Now in its third year, New York Valves is the world’s foremost educational forum for interventionalists, surgeons, and clinical cardiologists dedicated to the field of structural heart disease.

Wednesday, June 24, 2026

Late-Breaking Clinical Science: TAVR Session I

10:15 AM — 11:45 AM EDT

7-Year Valve Durability in the PARTNER 3 Trial

Philippe Pibarot

Seven-Year TAVR Outcomes in Low-Risk Patients treated with Balloon-Expandable Valves in the United States

Sreekanth Vemulapalli

Outcomes of TAVR with the Evolut Platform: Results from the VA-CART Program

Neel Butala

8-Year Durability and Reintervention with the Evolut Valve: Single-Center Results

Sachin S. Goel

6-Year Outcomes from the Evolut TAVR Low-Risk Bicuspid Study

Basel Ramlawi

TAVR for Asymptomatic Severe AS: Updated Results from the EARLY-TAVR trial

Philippe Genereux

 

Late-Breaking Clinical Science: Tricuspid

1:45 PM — 2:45 PM EDT

Transcatheter Tricuspid Valve Replacmement after Failed T-TEER: The REDEMPTION registry

Prasham Dave

Treatment Pathways and Outcomes in TRISCEND-Ineligible Patients: A Single-Center Study

Ashtyn N. Williams

Thirty-day Outcomes After T-TEER with the TriClip System: Early Experience from the TVT Registry

Wayne Batchelor

Valve Thrombosis after TTVR: The TRIPLACE Registry

Julio Echarte Morales

 

Thursday, June 25, 2026

Late-Breaking Clinical Science: Mitral

10:15 AM — 11:45 AM EDT

One-Year Outcomes of M3 TMVR in Patients with Mitral Annular Calcification: The ENCIRCLE-MAC

Mayra Guerrero

LAMPOON Trends and Outcomes: Insights from the STS/ACC TVT Registry

Jaffar M. Khan

One-Year Outcomes of PASCAL M-TEER: Real-World Evidence from the TVT Registry

Azeem Latib

Repeat M-TEER in the TVT Registry: Temporal Trends, Predictors, and Outcomes

John Thomas Saxon

Real-World Evaluation of MitraClip vs. PASCAL for M-TEER

Pier Pasquale Leone

M-TEERr for Patients With a Small Mitral Valve Orifice Area: The REPAIR Study

Philipp von Stein

 

Late-Breaking Innovation I

1:45 PM — 2:45 PM EDT

AI-Enabled ECG analysis for Detection and Prediction of Structural Heart Disease

Hak Seung Lee

EVolution Of heart vaLVe teams and the patient Experience (EVOLVE): A Multicenter, Mixed Methods Study of TAVR Programs Across the United States

Dhaval Kolte

Real-World Outcomes of the Shortcut Device for Leaflet Modification Prior to ViV TAVR

Raj R. Makkar

BASILICA Trends and Outcomes: Insights from the STS/ACC TVT Registry

Jaffar M. Khan

 

Friday, June 26, 2026

Late-Breaking Clinical Science: TAVR Session II

10:15 AM — 11:45 AM EDT

Baseline Clinical and Echocardiographic Characteristics among Moderate AS Patients Enrolled in the PROGRESS Trial

Raj R. Makkar

Measuring Quality in the Evaluation, Surveillance, and Treatment of Aortic Stenosis: First Large-Scale Report from the AHA Target AS Initiative

Brian R. Lindman

A Prospective Multicenter Study of an EHR-Facilitated Valve Care Pathway for Severe Aortic Stenosis: The DETECT AS II Study

Sammy Elmariah

Real-World Outcomes of TAVR with the NAVITOR valve for Patients with Small Aortic Annuli: Results from the STS/ACC Registry

Raviteja Reddy Guddeti

A Randomized Trial Comparing Femoral or Radial Secondary Access in TAVR

Antony Walton

New Permanent Pacemaker Implantation After TAVR for Pure Aortic Regurgitation: Results from the ALIGN-AR Study

James M. McCabe

 

Late-Breaking Innovation II

1:45 PM — 2:45 PM EDT

Pulsed Field Ablation of the LAA Prior to LAA Closure: A Novel Approach to Reduce Peri-Device Leak

Vivek Y. Reddy

M-TEER vs. Valve-In-Ring in Patients with Failed Surgical Mitral Valve Repair: Insights from the REDO-MR Registry

Guido Ascione

Six-Month Outcomes of Mitral Valve Lithotripsy using the SMARTCRACK Balloon for Mitral Stenosis with Severe Mitral Annular or Valvular Calcification: The SMART-MAC trial

Kent Chak-yu So

TAVR with the JenaValve Trilogy System in Patients with Continous-Flow LVADS: The JENA-VAD NOW Registry

Ravi Ramana

In addition to late-breaking research, New York Valves will feature:

• Live cases showcasing groundbreaking procedures performed by world-renowned operators from prestigious medical institutions
• 180+ scientific abstracts
• 220+ challenging cases
• Returning for a second year, the LAAC Summit is a high-impact program featuring real-world case reviews and live cases with critical insights from leading experts. 
• And much more!